Skip to main content
Equibles

GMAB · Genmab A/S · Metrics

Track GMAB — free

Use GMAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GMAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$37.39 -1.09 (-2.83%) At close · Oct 6
Rebalance outlook locked
Market Cap
$21.72B
Shares
614.90M
Volume · Oct 6 6.6M Avg daily vol (3M) 2.69M

GMAB metrics

63 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$38.48
Market cap
$21.72B

Price action

20 metrics
Price change (1W)
+8.8%
Price change (30D)
+14.8%
Price change (3M)
+37.4%
Price change (6M)
+38.7%
Price change (YTD)
+24.9%
Price change (1Y)
+14.7%
Trailing year
Price change (5Y)
-10.0%
52-week high
$38.48
52-week low
$23.85
Change from 52-week high
+0.0%
Change from 52-week low
+61.3%
Annualized volatility
34.6%
Annualized volatility (3M)
34.7%
Beta
0.8
RSI (14D)
74.6
Price vs SMA 50
+17.1%
Price vs SMA 200
+29.7%
Avg volume (3M)
2.69M
Relative volume
4.6
Average dollar volume
$87.76M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
614.90M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
5.3×
reciprocal yield 19.0%
P / book
3.6
reciprocal yield 27.4%
FCF yield
4.0%
TTM · current market cap
Buyback yield
—
P / FCF
25.0
reciprocal yield 4.0%
P / operating cash flow
24.4
reciprocal yield 4.1%
Earnings yield
3.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
93.0%
Operating margin
26.0%
Trailing 12 months
Net margin
19.1%
Gross profit (TTM)
—
Operating profit (TTM)
$1.07B
Net income (TTM)
$788.00M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
21.0%
Effective tax rate
13.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+24.9%
Year over year
Net income growth YoY
-9.8%
Revenue (TTM)
$4.13B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
13.2%
Return on assets
6.3%
Debt / equity
—
Current ratio
2.5
EBITDA (TTM)
—
Free cash flow (TTM)
$869.00M
Quick ratio
2.4
Interest coverage
2.5
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.50B
Total assets
$12.52B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$891.00M
Capital expenditures (TTM)
$22.00M
R&D (TTM)
$1.78B
SG&A (TTM)
—
Stock compensation (TTM)
$156.00M
R&D / revenue
43.1%
Stock compensation / revenue
3.8%

Ownership (13F)

3 metrics
13F filers
293
13F filer change QoQ
+15
Institutional ownership
17.4%

Short interest

3 metrics
Short interest
0.8%
Latest settlement · 3.2 days to cover
Days to cover
3.2d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1434265 CUSIP 372303206 13F (30d) 8 filings 8 filers Visit website Investor relations